

Tuberculosis profile: Lao People's Democratic Republic

Population 2021: 7.4 million

Estimates of TB burden*, 2021

	Number	(Rate per 100 000 population)
Total TB incidence	11 000 (6 800-15 000)	143 (91-208)
HIV-positive TB incidence	610 (380-900)	8.3 (5.2-12)
MDR/RR-TB incidence**	98 (46-150)	1.3 (0.61-2)
HIV-negative TB mortality	2 000 (1 200-3 100)	27 (16-41)
HIV-positive TB mortality	240 (150-340)	3.2 (2-4.6)

Estimated proportion of TB cases with MDR/RR-TB*, 2021

New cases	0.67% (0.49-0.87)
Previously treated cases	11% (7.9-15)

Universal health coverage and social protection*

TB treatment coverage (notified/estimated incidence), 2021	58% (40-91)
TB patients facing catastrophic total costs, 2019	63% (58-67)
TB case fatality ratio (estimated mortality/estimated incidence), 2021	22% (11-36)

TB case notifications, 2021

Total new and relapse	6 123
- % tested with rapid diagnostics at time of diagnosis	96%
- % with known HIV status	85%
- % pulmonary	94%
- % bacteriologically confirmed ^	70%
- % children aged 0-14 years	1%
- % women (aged ≥15 years)	36%
- % men (aged ≥15 years)	63%
Total cases notified	6 200

TB/HIV care in new and relapse TB patients, 2021

	Number	(%)
Patients with known HIV status who are HIV-positive	301	5.8%
- on antiretroviral therapy	210	70%

Drug-resistant TB care**, 2021

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	100%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	100%
Laboratory-confirmed cases - MDR/RR-TB ^^	44
Patients started on treatment - MDR/RR-TB ^^	36
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB ^^	0
Patients started on treatment - pre-XDR-TB or XDR-TB ^^	0
MDR/RR-TB cases tested for resistance to any fluoroquinolone	29

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2020	89%	8 002
Previously treated cases, excluding relapse, registered in 2020	74%	110
HIV-positive TB cases registered in 2020	77%	369
MDR/RR-TB cases started on second-line treatment in 2019	77%	39
Pre-XDR-TB/XDR-TB cases started on second-line treatment in 2019		0


TB preventive treatment, 2021

% of HIV-positive people (newly enrolled in care) on preventive treatment	38%
% of children (aged < 5 years) household contacts of bacteriologically-confirmed TB cases on preventive treatment	8.2% (7.5-9)


Funding for TB

Funding for TB, 2021 (US\$ millions)	2
- % domestic funding	34%
- % international funding	66%


Incidence, New and relapse TB cases notified, HIV-positive TB incidence (Rate per 100 000 population per year)




HIV-negative TB mortality (Rate per 100 000 population per year)




Incidence, Notified cases by age group and sex, 2021



Cases attributable to five risk factors, 2021



Funding for TB (US\$ millions)



* Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.
** RR is TB resistant to rifampicin (R), MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone
^ Calculated for pulmonary cases only
^^ Includes cases with unknown previous TB treatment history
^^^ Includes patients diagnosed before 2021 and patients who were not laboratory-confirmed

Generated 2022-11-28 by the World Health Organization (<https://www.who.int/teams/global-tuberculosis-programme/data>)